Details for Patent: 6,890,927
✉ Email this page to a colleague
Title: | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Abstract: | The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene: ##STR1## and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs. |
Inventor(s): | Bogle; David E. (Jewett City, CT), Rose; Peter R. (Ledyard, CT), Williams; Glenn R. (East Aurora, NY) |
Assignee: | Pfizer Inc (New York, NY) |
Filing Date: | May 06, 2002 |
Application Number: | 10/139,730 |
Claims: | 1. The tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca -2(11),3,5,7,9-pentaene. 2. A compound according to claim 1 which is the L-tartrate salt. 3. A compound according to claim 2 which is anhydrous. 4. A compound according to claim 1 which is the D,L-tartrate salt. 5. A compound according to claim 4 which is anhydrous. 6. A compound according to claim 1 which is D-tartrate salt. 7. A compound according to claim 6 which is anhydrous. 8. A compound according to claim 6 which is a hydrate. 9. A compound according to claim 1 which is the meso-tartrate salt. 10. The L-tartrate salt of claim 2 that is a hydrate. 11. A compound according to claim 10 where the hydrate is a monohydrate. 12. A D,L-tartrate of claim 4 which is a hydrate. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1, 2, 6 or 9. 14. A method of treatment for nicotine dependency, addiction and withdrawal comprising the administration of a compound according to any of claims 1, 2, 6 or 9 to a subject in need thereof. 15. A process for the preparation of a compound according to claim 1 comprising the steps of (i) contacting 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with between about 1 and about 2 equivalents of L-tartaric acid; and (ii) collecting the crystals formed. 16. A process according to claim 15 wherein 1.1 equivalents of L-tartaric acid are employed and the tartaric acid is added to a solution containing the free base. 17. A process according to claim 15 wherein the contacting step is allowed to proceed above 45.degree. C. 18. A process according to claim 15 wherein the contacting step is allowed to proceed for less than 2 hours. 19. A process according to claim 15 wherein the suitable solvent is selected from the group consisting of an (C.sub.1 -C.sub.6)alkyl alcohol, an (C.sub.1 -C.sub.6)alkyl ketone, an (C.sub.1 -C.sub.6)alkyl ether, acetonitrile and an (C.sub.1 -C.sub.6)alkyl ester. 20. A process according to claim 15 wherein the suitable solvent is ethanol or methanol. 21. A process for the preparation of a compound according to claim 1 comprising the steps of (i) contacting 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with between about 1 and about 2.3 equivalents of L-tartaric acid; and (ii) collecting the crystals formed. 22. A process according to claim 21 wherein 1.1 equivalents of L-tartaric acid are employed and the free base in solution is added to a solution containing L-tartaric acid. 23. A process according to claim 21 wherein the contact step is allowed to proceed for at least 2 hours. 24. A process according to claim 21 wherein the contact step is allowed to proceed for at least 12 hours. 25. A process according to claim 21 wherein the suitable solvent is selected from the group consisting of an (C.sub.1 -C.sub.6)alkyl alcohol, an (C.sub.1 -C.sub.6)alkyl ketone, an (C.sub.1 -C.sub.6)alkyl ether, acetonitrile and an (C.sub.1 -C.sub.6)alkyl ester. 26. A process according to claim 21 wherein the suitable solvent is methanol or ethanol. 27. A process according to claim 21 wherein the suitable solvent is methanol. 28. A process for the preparation of a compound according to claim 16 comprising the steps of (i) contacting an anhydrous L-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene with water; and (ii) collecting the crystals formed. 29. A process according to claim 28 wherein the contacting of step (i) comprises exposing the anhydrous L-tartrate salt to greater than 70% humidity. 30. A process according to claim 28 wherein the contacting of step (i) comprises slurrying the anhydrous L-tartrate salt with water. 31. A process according to claim 28 wherein step (i) comprises the addition of an organic solvent. 32. A process according to claim 28 wherein step (i) comprises the addition of methanol, ethanol or acetonitrile. 33. A process for the preparation of a compound according to claim 25 comprising the steps of (i) contacting 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with about 1 to about 2.3 equivalents of D,L-tartaric acid; and (ii) collecting the crystals formed. 34. A process according to claim 33 wherein about 2.2 equivalents of D,L-tartaric acid is employed and the free base in solution is added to a solution containing D,L-tartaric acid. 35. A process according to claim 33 wherein the contact step is allowed to proceed for at least 24 hours. 36. A process according to claim 33 wherein the suitable solvent is anhydrous ethanol. 37. A process for the preparation of a compound according to claim 12 comprising the steps of (i) contacting 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with about 1 to about 2.3 equivalents of D,L-tartaric acid; and (ii) collecting the crystals formed. 38. A process according to claim 37 wherein about 2.2 equivalents of D,L-tartaric acid is employed and the free base in solution is added to a solution containing D,L-tartaric acid. 39. A process according to claim 37 wherein the contact step is allowed to proceed for at least 24 hours. 40. A process according to claim 37 wherein the suitable solvent is 20% aqueous ethanol. |